• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    New insider Salus Thomas D. claimed no ownership of stock in the company (SEC Form 3)

    4/16/25 4:37:56 PM ET
    $LFCR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LFCR alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Salus Thomas D.

    (Last) (First) (Middle)
    C/O LIFECORE BIOMEDICAL, INC.
    3515 LYMAN BLVD.

    (Street)
    CHASKA MN 55318

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/14/2025
    3. Issuer Name and Ticker or Trading Symbol
    LIFECORE BIOMEDICAL, INC. \DE\ [ LFCR ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Legal & Administration
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    No Security beneficially owned 0 D
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    /s/ Rebecca Hilt, Attorney-In-Fact for Thomas D Salus 04/16/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $LFCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $LFCR

    DatePrice TargetRatingAnalyst
    5/21/2025Outperform
    William Blair
    9/5/2024$8.00Buy
    Craig Hallum
    8/28/2024Outperform → Mkt Perform
    Barrington Research
    3/20/2023$11.00 → $2.00Overweight → Equal-Weight
    Stephens
    More analyst ratings

    $LFCR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on Lifecore Biomedical

      William Blair initiated coverage of Lifecore Biomedical with a rating of Outperform

      5/21/25 8:58:30 AM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Craig Hallum initiated coverage on Lifecore Biomedical with a new price target

      Craig Hallum initiated coverage of Lifecore Biomedical with a rating of Buy and set a new price target of $8.00

      9/5/24 8:50:10 AM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifecore Biomedical downgraded by Barrington Research

      Barrington Research downgraded Lifecore Biomedical from Outperform to Mkt Perform

      8/28/24 9:04:53 AM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFCR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner English Aron R. sold $9,132,503 worth of shares (1,386,060 units at $6.59) (SEC Form 4)

      4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

      5/28/25 8:06:01 PM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Josephs Paul covered exercise/tax liability with 21,532 shares, decreasing direct ownership by 4% to 538,185 units (SEC Form 4)

      4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

      5/22/25 1:43:07 PM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner English Aron R. sold $86,353 worth of shares (12,334 units at $7.00) (SEC Form 4)

      4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

      5/16/25 11:28:11 AM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFCR
    SEC Filings

    See more
    • Lifecore Biomedical Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

      4/16/25 4:40:21 PM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lifecore Biomedical Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

      4/10/25 4:46:15 PM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Lifecore Biomedical Inc.

      10-Q - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Filer)

      4/3/25 4:23:20 PM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $LFCR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Josephs Paul bought $97,580 worth of shares (17,000 units at $5.74), increasing direct ownership by 3% to 559,717 units (SEC Form 4)

      4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

      1/8/25 4:10:19 PM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Wynnefield Partners Small Cap Value Lp I bought $1,200,000 worth of shares (292,683 units at $4.10) (SEC Form 4)

      4 - LIFECORE BIOMEDICAL, INC. \DE\ (0001005286) (Issuer)

      10/7/24 8:45:10 PM ET
      $LFCR
      Biotechnology: Pharmaceutical Preparations
      Health Care